ICON recognised for specialised services offering across product development lifecycle
ICON received 2019 CRO Leadership Awards in five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall. In three categories, ICON took awards in all three groups.
- Compatibility (Overall, Big Pharma, Small Pharma)
- Expertise (Small Pharma)
- Phase IV (Overall, Big Pharma, Small Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma)
This builds on ICON’s success in 2018 when the company won a CRO Phase IV Leadership Award (Overall, Big Pharma).
For the 2019 CRO Leadership Awards, Life Science Leader magazine
again teamed up with
Survey participants were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with contract research organisations.
“These awards are a testament to the expertise of ICON’s operational and
scientific professionals, and demonstrate the ownership and outcomes
focus we bring to all phases of the drug development process. It is
especially pleasing to see us recognised both by big and small biopharma
companies alike, commented Dr
“These awards recognise ICON’s comprehensive services, spanning the entire product development lifecycle and providing seamless solutions that ultimately lead to better outcomes for our customers”.
“Life Science Leader is proud to once again be working with ISR
Reports to honor those CROs that have proven themselves to be the top
performers in Compatibility, Capabilities, Expertise,
“The winners are selected by their pharma clients, who rate their CROs on 20+ different performance metrics. We believe the CROs receiving an award this year are truly at the top of their class and are deserving of this recognition. Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of biopharmaceutical companies and their patients.”
“Industry Standard Research continues to consider it an honor to provide
the primary market research data for Life Science Leader’s CRO
Leadership Awards. ISR’s stringent screening processes ensures that only
highly qualified industry decision makers participate in our CRO
benchmarking market research,” commented
“This is paramount as we ask the research participants to provide experiential, not perceptual, feedback on their involvement with contract suppliers over the past 18 months. The data enables users of ISR’s market research to make confident business decisions based on the experiences of their industry peers.”
ICON previously received CRO Leadership Awards in 2018 and 2015.
A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
ICON Media Contact
+44 (0)20 7067 0548